Annals of Hematology

, Volume 88, Issue 11, pp 1099–1106 | Cite as

Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea

  • Moon Ki Choi
  • Hyun Jung Jun
  • Sung Yoon Lee
  • Kyung Ha Kim
  • Do Hyoung Lim
  • Kihyun Kim
  • Young Hyeh Ko
  • Won Seog Kim
  • Seok Jin Kim
Original Article

Abstract

Burkitt lymphoma (BL) is a rare subtype of adult non-Hodgkin lymphoma, so studies on the outcome of adult BL, especially in Asian patients, are scarce. We report our results using the LMB protocol on Korean adult BL patients. Thirty-eight newly diagnosed BL patients were treated with the LMB protocol; 29 males and nine females with a median age of 47 years (range 18–70) were analyzed, and 14 (36.8%) patients had central nervous system or bone marrow involvement. After the induction phase, 28 patients achieved complete response (CR, 73.7%) and five showed partial response (PR, 13.2%). Among those achieving CR, only four showed relapse. All of the non-CR patients died, including five PR and one with progressive disease. The other four patients died because of infection after the first course of induction. The progression-free and overall estimated survival at 5 years was 74.99% and 68.10%, respectively. Of the 12 patients who died, the median survival was 4.43 months (95% confidence interval 1.43–7.43 months). Thus, most deaths occurred shortly after diagnosis, and four patients older than 58 years died after the first induction cycle. Most early deaths were caused by treatment-related morbidity and failure to achieve complete response. B symptoms, advanced age, bone marrow involvement, and St. Jude/Murphy stage IV classification were significantly associated with poor overall survival. In conclusion, the LMB protocol was effective for Korean adult BL patients. However, considering the high incidence of treatment-related deaths and the poor outcome of non-CR patients, risk-adapted modification of the induction phase is warranted.

Keywords

Burkitt lymphoma Chemotherapy Prognosis 

References

  1. 1.
    Magrath I (1990) The pathogenesis of Burkitt’s lymphoma. Adv Cancer Res 55:133–270. doi:10.1016/S0065-230X(08) 60470-4 PubMedCrossRefGoogle Scholar
  2. 2.
    Bishop PC, Rao VK, Wilson WH (2000) Burkitt’s lymphoma: molecular pathogenesis and treatment. Cancer Invest 18:574–583. doi:10.3109/07357900009012197 PubMedCrossRefGoogle Scholar
  3. 3.
    Kian TC, Miriam T, Richard Q et al (2008) Clinical characteristics, prognostic factors and outcomes of Burkitt lymphoma in adult Asians. Leuk Lymphoma 49:824–827. doi:10.1080/10428190701882948 PubMedCrossRefGoogle Scholar
  4. 4.
    Park YH, Kim WS, Kang HJ et al (2006) Gastric Burkitt lymphoma is a distinct subtype that has superior outcomes to other types of Burkitt lymphoma/leukemia. Ann Hematol 85:285–290. doi:10.1007/s00277-005-0050-8 PubMedCrossRefGoogle Scholar
  5. 5.
    Blum KA, Lozanski G, Byrd JC (2004) Adult Burkitt leukemia and lymphoma. Blood 104:3009–3020. doi:10.1182/blood-2004-02-0405 PubMedCrossRefGoogle Scholar
  6. 6.
    Ferry JA (2006) Burkitt’s lymphoma: clinicopathologic features and differential diagnosis. Oncologist 11:375–383. doi:10.1634/theoncologist.11-4-375 PubMedCrossRefGoogle Scholar
  7. 7.
    Divine M, Lepage E, Briere J et al (1996) Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. Groupe Etude Lymphomes Adulte J Clin Oncol 14:240–248Google Scholar
  8. 8.
    Longo DL, Duffey PL, Jaffe ES et al (1994) Diffuse small noncleaved-cell, non-Burkitt’s lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. J Clin Oncol 12:2153–2159PubMedGoogle Scholar
  9. 9.
    Patte C, Philip T, Rodary C et al (1986) Improved survival rate in children with stage III and IV B cell non-Hodgkin’s lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol 4:1219–1226PubMedGoogle Scholar
  10. 10.
    Patte C, Auperin A, Michon J et al (2001) The Societe Francaise d’Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood 97:3370–3379. doi:10.1182/blood.V97.11.3370 PubMedCrossRefGoogle Scholar
  11. 11.
    Philip T, Meckenstock R, Deconnick E et al (1992) Treatment of poor prognosis Burkitt’s lymphoma in adults with the Societe Francaise d’Oncologie Pediatrique LMB Protocol–a study of the Federation Nationale des Centres de Lutte Contre le Cancer (FNLCC). Eur J Cancer 28A:1954–1959. doi:10.1016/0959-8049(92) 90235-T PubMedCrossRefGoogle Scholar
  12. 12.
    Divine M, Casassus P, Koscielny S et al (2005) Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol. Ann Oncol 16:1928–1935. doi:10.1093/annonc/mdi403 PubMedCrossRefGoogle Scholar
  13. 13.
    Harris NL, Jaffe ES, Diebold J et al (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 17:3835–3849PubMedGoogle Scholar
  14. 14.
    Soussain C, Patte C, Ostronoff M et al (1995) Small noncleaved cell lymphoma and leukemia in adults. A retrospective study of 65 adults treated with the LMB pediatric protocols. Blood 85:664–674PubMedGoogle Scholar
  15. 15.
    Murphy SB (1980) Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol 7:332–339PubMedGoogle Scholar
  16. 16.
    Patte C, Philip T, Rodary C et al (1991) High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 9:123–132PubMedGoogle Scholar
  17. 17.
    Kim K, Johnson JA, Derendorf H (2004) Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol 44:1083–1105. doi:10.1177/0091270004268128 PubMedCrossRefGoogle Scholar
  18. 18.
    Lee EJ, Petroni GR, Schiffer CA et al (2001) Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 19:4014–4022PubMedGoogle Scholar
  19. 19.
    Thomas DA, Cortes J, O’Brien S et al (1999) Hyper-CVAD program in Burkitt’s-type adult acute lymphoblastic leukemia. J Clin Oncol 17:2461–2470PubMedGoogle Scholar
  20. 20.
    Lopez TM, Hagemeister FB, McLaughlin P et al (1990) Small noncleaved cell lymphoma in adults: superior results for stages I-III disease. J Clin Oncol 8:615–622PubMedGoogle Scholar
  21. 21.
    Mead GM, Barrans SL, Qian W et al (2008) A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 112:2248–2260. doi:10.1182/blood-2008-03-145128 PubMedCrossRefGoogle Scholar
  22. 22.
    Thomas DA, Faderl S, O’Brien S et al (2006) Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 106:1569–1580. doi:10.1002/cncr.21776 PubMedCrossRefGoogle Scholar
  23. 23.
    Mead GM, Sydes MR, Walewski J et al (2002) An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 13:1264–1274. doi:10.1093/annonc/mdf253 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Moon Ki Choi
    • 1
  • Hyun Jung Jun
    • 1
  • Sung Yoon Lee
    • 1
  • Kyung Ha Kim
    • 1
  • Do Hyoung Lim
    • 1
  • Kihyun Kim
    • 1
  • Young Hyeh Ko
    • 2
  • Won Seog Kim
    • 1
  • Seok Jin Kim
    • 1
  1. 1.Division of Hematology-Oncology, Department of Medicine Samsung Medical CenterSungkyunkwan University School of MedicineSeoulSouth Korea
  2. 2.Department of Pathology, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulKorea

Personalised recommendations